Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1(*)6 or UGT1A1(*)28

PURPOSE: The relationship between the pharmacokinetics of irinotecan and outcomes of advanced colorectal cancer is unclear, and few studies have examined individualized irinotecan-based chemotherapy depending on plasma 7-ethyl-10-hydroxy camptothecin (SN-38) levels and dihydropyrimidine dehydrogenas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Chuan, Ying, Haifeng, Zhuang, Rongyuan, Zhang, Xiaowei, Lu, Hongmin, Wang, Hui, Wang, Shuowen, Li, Qi, Wang, Chungang, Cai, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257074/
https://www.ncbi.nlm.nih.gov/pubmed/30538568
http://dx.doi.org/10.2147/CMAR.S176918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257074/
https://www.ncbi.nlm.nih.gov/pubmed/30538568
http://dx.doi.org/10.2147/CMAR.S176918

Ejemplares similares